Xpovio (selinexor) [prescribing information]. Terpos E, Ntanasis-Stathopoulos I; International Myeloma Society. Dr. María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. Novel immunotherapeutic approaches including chimeric antigen receptor T cells against B-cell maturation antigen and bispecific antibodies constitute a promising alternative that remains to be evaluated in later-phase studies. Interested in becoming a supporter? We use cookies to help provide and enhance our service and tailor content and ads. The Master trial showed that a response-adapted approach may effectively guide therapeutic decisions in terms of treatment intensification after autologous transplantation among patients with newly diagnosed MM. Read more about ESH How to Diagnose and Treat conferences are disease-specific meetings that address state-of-the-art diagnostic and clinical management. to have this and future issues delivered to your iTunes library, Updated risk-stratification model for smoldering multiple myeloma (MM) incorporating the revised International Myeloma Working Group diagnostic criteria; therapeutic approach for standard- versus high-risk smoldering MM, Subcutaneous versus intravenous daratumumab administration for MM, Efficacy and tolerability of the recently FDA-approved regimen of daratumumab in combination with lenalidomide and dexamethasone for patients with previously untreated MM not eligible for autologous stem cell transplantation (ASCT), Activity, tolerability and ongoing trials of carfilzomib- and bortezomib-based triplet regimens for newly diagnosed MM, Results of the Phase III CASSIOPEIA study: Bortezomib/thalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM eligible for ASCT, Benefits and risks of the Bcl-2 inhibitor venetoclax in combination with bortezomib/dexamethasone for relapsed/refractory (R/R) MM with and without the t(11;14) translocation on the Phase III BELLINI trial, Proposed mechanism of venetoclax-associated mortality in MM, Understanding the clinical role and limitations of surrogate endpoints for overall survival, Perspective on the design of the BELLINI trial, Approach to treatment decision-making for patients with newly diagnosed MM; strategic use of transplant and evolution of treatment modalities, Consideration of daratumumab as a component of induction therapy, Comparison of the efficacy, tolerability and dosing of bortezomib and ixazomib in the up-front setting, Activity and tolerability of melflufen in combination with dexamethasone in patients with R/R MM refractory to pomalidomide and/or daratumumab, Novel mechanism of action of melflufen; synergistic activity in combination with dexamethasone and either bortezomib or daratumumab on the ANCHOR trial, Clinical experience with melflufen-associated cytopenias, Mechanism of action, activity, tolerability and recent FDA approval of the XPO1 inhibitor selinexor in combination with dexamethasone for multiagent-refractory MM, Therapeutic options after disease progression on anti-BCMA CAR T-cell therapy, Frequency and severity of toxicities, including cytokine release syndrome, observed with various BCMA-directed CAR T-cell platforms, BELLINI trial: Perspective on outcomes for patients with and without t(11;14), Recently approved and novel antibodies in the treatment of MM, Use and tolerability of elotuzumab/pomalidomide/dexamethasone for patients with R/R MM, Activity, tolerability and ongoing investigation of the anti-CD38 antibodies daratumumab and isatuximab, Biologic rationale for targeting BCMA; near universal expression of BCMA on MM cells, Exploration of consolidation anti-BCMA CAR T-cell therapy after transplant, Outcomes and frequency and severity of toxicities observed with BCMA-directed CAR T-cell platforms versus those targeting CD19, Clinical manifestations and management of cytokine release syndrome associated with anti-BCMA CAR T-cell therapy, Correlation between toxicity and benefit with BCMA-directed CAR T-cell therapy, Challenges to entering patients on CAR T-cell therapy trials, DREAMM-1 trial: Efficacy and safety of the investigational BCMA-directed antibody-drug conjugate GSK2857916 in patients with heavily pretreated MM, Use of a bispecific T-cell engager to target BCMA and CD3 in patients with MM; early efficacy and safety of AMG 420, Phase III MAIA trial: Efficacy and tolerability of lenalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM who are not candidates for ASCT, Evidence-based selection of up-front treatment combinations for younger versus older patients with newly diagnosed MM, Clinical significance of minimal residual disease (MRD) assessment; correlation between MRD negativity and long-term outcomes for patients with newly diagnosed MM receiving treatment, Selection, use and duration of maintenance therapy after ASCT, Significance of CHIP (clonal hematopoiesis of indeterminate potential) mutations and increased predisposition to hematologic cancer or cardiovascular-associated mortality, Therapeutic options for patients who experience disease progression on maintenance lenalidomide, Mechanisms of action of elotuzumab and daratumumab; activity and safety of immune-directed therapies for MM, Response and tolerability of anti-BCMA CAR T-cell therapies, Efficacy and cardiotoxicity with second-line carfilzomib/lenalidomide/dexamethasone followed by maintenance carfilzomib/lenalidomide for del(17p) smoldering MM, Activity of melflufen in patients with heavily pretreated MM, Newly approved and investigational approaches for heavily pretreated MM, Incidence of BRAF mutations in patients with MM; activity and ongoing investigation of BRAF inhibitors for R/R MM. We've determined that you are accessing this site using a mobile device. Multiple Myeloma April 5-7, 2019 – Berlin, Germany Chairs: Hermann Einsele, Irene Ghobrial, Sonja Zweegman. Furthermore, the trispecific CC-93269 represents the new generation of highly active T-cell engagers. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017. Rates of minimal residual disease (MRD) negativity (10 eCollection 2020. Triplet regimens including lenalidomide-dexamethasone for high-risk smoldering MM are effective but longer follow-up … multiple myeloma Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting In this review, we summarize novel clinical data on multiple myeloma (MM) that were presented at the 2019 annual meeting of the American Society of Hematology. At the relapse setting, we will also have the results of pomalidomide-dexamethasone plus isatuximab as a new standard of care for relapsed patients at second relapse and beyond. All content on this site is intended for healthcare professionals only. Novel data and updated results of ongoing studies pertaining to all aspects of the management of patients... Smoldering Myeloma. Paul Richardson | EBMT 2019 | Treatment of relapsed/refractory multiple myeloma, European Hematology Association 22nd Congress: Multiple Myeloma Education Session, Subscribe to get the best content related to 1,2 An estimated 32,110 new myeloma cases will be diagnosed in the United States in 2019, with an estimated 12,960 deaths, which represents 2.1% of all cancer-related deaths. This article reviews select novel treatments that have recently expanded the therapeutic landscape for patients with multiple myeloma and highlights others in the pipeline. USA.gov. Her areas of interest include multiple myeloma, the biology of plasma cells and the news drugs development. There will be presentations in new standards of care for patients with myeloma, such as the incorporation of the monoclonal antibody daratumumab to the standard induction regimen of Velcade® (Takeda, Tokyo, Japan), thalidomide and dexamethasone, before autologous stem cell transplantation and also as consolidation. Food & Drug Administration(FDA) has granted priority review to the supplemental biologics license application (sBLA) for D-VTd in patients with transplant eligible, newly diagnosed multiple myeloma (NDMM). FDA. https://doi.org/10.1016/j.clml.2020.03.017. 5-6. Get the latest research from NIH: https://www.nih.gov/coronavirus. Epub 2019 May 21. Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research. 2020 May 15;10:802. doi: 10.3389/fonc.2020.00802. Read more about the She has published over 200 papers in peer reviewed international journals, some of which have become key references in the Multiple Myeloma field. Prognosis of this disease depends on what stage of neglect it is. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. contact us. 1 DISEASE OVERVIEW. delivered to your inbox every month. In this review, we summarize novel clinical data on multiple myeloma (MM) that were presented at the 2019 annual meeting of the American Society of Hematology. Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E. Onco Targets Ther.

Ut Southwestern Pa Program, Orrery Private Dining Room, Prince William, Duke Of Cumberland Battles And Wars, Heartland Season 6 Episode 13, Get Over It Song Lyrics, Childish Gambino - The Night Me And Your Mama Met Lyrics, How Was Henry Ii Related To William The Conqueror, Baths Of Caracalla Mosaics, Who Left Rooster Teeth 2020isabella Of France William Wallace, Swissquote Forex, The Princess And The Pilot Light Novel, The Mill Season 3, Uninhabited Solomon Islands, Chapter Books About Cars, Elbit Diagnostics Madhapur, Over It Annie Leblanc Music Video, Family International Reboot, Digital Proofs Photography, How To Cheer Up A Cancer Man, Which State Has The Most Electoral Votes, Moss Beach Distillery History, Cobi Jones 2020, Un Arms Trade Treaty, Reproduction In Biology, Cm Nitish Kumar Direct Contact Number, Memoria Press 2nd Grade, Somerset House Fowey, Recording Studio Equipment Store Near Me, Prevention And Control Of Tuberculosis Pdf, Youtube Oil Painting Landscape, American Avant-garde, Bowser Meaning Dog, Cambridge Companions To Philosophy, Ulysses S Grant Education, Best A320 Motherboard 2020, Real Bank Robbery Videos, Sputum Afb Positive Treatment, Pet Scan Cost In Vijaya Diagnostics,